Safety and Efficacy of Amiodarone in a Patient With COVID-19
Nadia Castaldo, MD, Alberto Aimo, MD, Vincenzo Castiglione, MD and 3 more
JACC: Case Reports · 2020
doi:10.1016/j.jaccas.2020.04.053 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
There is an urgent need for effective treatments for coronavirus disease-2019 (COVID-19). Amiodarone, like hydroxychloroquine, exerts antiviral actions by interfering with endocytosis and viral replication. Here, to our knowledge, we report the first case of a patient affected by respiratory failure related to COVID-19 who recovered after only supportive measures and a short amiodarone course. (Level of Difficulty: Beginner.)
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.